トレムフィア市場- 世界の産業規模、シェア、動向、機会、予測、用途別（尋常性乾癬、乾癬性関節炎、その他）、流通チャネル別、地域別、競合別、2020-2030年

トレムフィアの世界市場は、2024年に37億8,000万米ドルと評価され、CAGR 7.59%で2030年には58億7,000万米ドルに達すると予測されています。

トレムフィアの世界市場は、尋常性乾癬や乾癬性関節炎などの慢性自己免疫疾患の管理における標的生物学的治療薬に対する需要の高まりによって、着実な成長を遂げています。IL-23阻害剤であるトレムフィアは、その高い有効性、良好な安全性プロファイル、簡便な投与スケジュールにより、患者のアドヒアランスと治療成績を向上させることから、大きな注目を集めています。世界的にこれらの疾患の有病率が高まっていることに加え、患者やヘルスケア専門家の間で標的免疫療法の利点に対する認識が高まっていることが、市場の拡大に寄与しています。製薬企業は、他の炎症性疾患への応用を含め、より広範な治療の可能性を探るため、先進的な調査や臨床試験に投資しています。中等度から重度の症例に生物学的製剤を推奨する治療ガイドラインの拡大が、採用率をさらに押し上げています。

この市場では、治療効果を維持しながら投与回数を減らす長時間作用型の生物学的製剤へのシフトが進んでおり、トレムフィアの月1回または四半期ごとの投与スケジュールに合致しています。生物学的製剤とドラッグデリバリーシステムの絶え間ない進歩が、患者のコンプライアンスと治療満足度の向上を支えています。また、患者教育の改善、治療経路の最適化、保険適用や償還プログラムによるアクセス拡大を目的とした製薬メーカーとヘルスケアプロバイダーとの連携も顕著に増加しています。競合力学は、市場浸透の強化とアンメットニーズへの対応を目的とした、継続的な製品革新、パイプラインの拡充、戦略的提携によって形成されています。さらに、個別化医療への注目の高まりは、臨床医が複雑な免疫介在性疾患患者に対してより正確で効果的な治療選択肢を求めていることから、トレムフィアのような標的治療の開発を後押ししています。

有望な成長見通しにもかかわらず、世界のトレムフィア市場はいくつかの課題に直面しています。特に中低所得地域では、高い治療費が依然として大きな障壁となっており、患者への幅広いアクセスを制限しています。バイオシミラーに対する特許の独占権や規制上の要件により、当面は競争的な価格設定が制限され、コスト関連の制約が長引く可能性があります。また、患者によっては治療効果にばらつきが生じ、別の治療戦略が必要になることもあります。市場は、IL-17やTNF阻害剤のような同様の経路を標的とする他の生物製剤や低分子医薬品との激しい競争にさらされており、特定の患者セグメントにおけるトレムフィアの採用に影響を与える可能性があります。さらに、新たな適応症の承認には時間がかかり複雑であるため、市場拡大の機会を遅らせる可能性があります。価格戦略、患者支援プログラム、継続的な臨床研究を通じてこれらの課題に対処することが、予測期間中の成長を維持するために極めて重要です。

主要市場促進要因

慢性炎症性疾患の有病率の上昇

主な市場課題

高い治療費

主要市場動向

IL-23阻害剤の採用増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のトレムフィア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 用途別（尋常性乾癬、乾癬性関節炎（PsA）、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のトレムフィア市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のトレムフィア市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のトレムフィア市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のトレムフィア市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのトレムフィア市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Johnson & Johnson Services, Inc.
• Coherus BioSciences
• Amgen Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Pfizer Inc.
• AstraZeneca plc
• Sanofi S.A.
• Bristol-Myers Squibb

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Tremfya Market was valued at USD 3.78 Billion in 2024 and is expected to reach USD 5.87 Billion by 2030 with a CAGR of 7.59%. The Global Tremfya Market is witnessing steady growth, driven by rising demand for targeted biologic therapies in managing chronic autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Tremfya, an IL-23 inhibitor, has gained significant attention due to its high efficacy, favorable safety profile, and convenient dosing schedule, which enhance patient adherence and treatment outcomes. Growing prevalence of these conditions worldwide, coupled with increasing awareness among patients and healthcare professionals about the benefits of targeted immunology therapies, is contributing to the market's expansion. Pharmaceutical companies are investing in advanced research and clinical trials to explore the broader therapeutic potential of Tremfya, including its application in other inflammatory disorders. Expanding treatment guidelines that recommend biologics for moderate-to-severe cases are further boosting adoption rates.

The market is experiencing a shift toward long-acting biologics that reduce dosing frequency while maintaining therapeutic effectiveness, aligning well with Tremfya's monthly or quarterly administration schedule. Continuous advancements in biologic drug formulation and delivery systems are supporting better patient compliance and treatment satisfaction. There is also a notable increase in collaborations between pharmaceutical manufacturers and healthcare providers to improve patient education, optimize treatment pathways, and expand access through insurance coverage and reimbursement programs. Competitive dynamics are being shaped by ongoing product innovation, pipeline expansions, and strategic partnerships aimed at enhancing market penetration and addressing unmet needs. Furthermore, the increasing focus on personalized medicine is encouraging the development of targeted therapies like Tremfya, as clinicians seek more precise and effective treatment options for patients with complex immune-mediated diseases.

Despite the promising growth prospects, the Global Tremfya Market faces several challenges. High treatment costs remain a major barrier, particularly in low- and middle-income regions, limiting broader patient access. Patent exclusivity and regulatory requirements for biosimilars may restrict competitive pricing in the near term, prolonging cost-related limitations. Some patients may also experience varying treatment responses, necessitating alternative therapeutic strategies. The market is subject to intense competition from other biologics and small molecule drugs targeting similar pathways, such as IL-17 and TNF inhibitors, which may impact Tremfya's adoption in certain patient segments. Additionally, the lengthy and complex drug approval process for new indications can delay market expansion opportunities. Addressing these challenges through pricing strategies, patient assistance programs, and continued clinical research will be crucial for sustaining growth in the forecast period.

Key Market Drivers

Rising Prevalence of Chronic Inflammatory Diseases

The rising prevalence of chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis is a compelling driver for the Global Tremfya Market. In the United States, psoriasis affects approximately 3.0% of adults, translating to over 7.5 million individuals, according to data from the National Health and Nutrition Examination Survey. Among these, a significant portion go on to develop psoriatic arthritis, which impacts roughly 0.41% of the U.S. adult population, equating to nearly 912,000 adults.

Inflammatory bowel diseases (IBD), encompassing Crohn's disease and ulcerative colitis, are diagnosed in approximately 721 per 100,000 Americans, or nearly 1 in 100, as reported by the Crohn's & Colitis Foundation in a comprehensive U.S. population-based study. Strong diagnostic data reinforces the growing burden of these conditions. These diseases are often chronic and debilitating, underscoring the importance of effective long-term treatment strategies. Tremfya's targeted mechanism of selectively inhibiting the p19 subunit of interleukin-23 addresses the underlying inflammatory pathways more precisely than older systemic therapies. This precision results in favorable safety and efficacy outcomes, making Tremfya an appealing treatment for both clinicians and patients seeking better disease control and improved quality of life.

Rising obesity rates, environmental stressors, and an aging population contribute to increasing incidence and prevalence of these immune-mediated conditions. Healthcare systems emphasize early intervention to prevent disease progression, reduce flare-ups, and minimize complications such as joint damage or gastrointestinal scarring. Demand remains strong for biologics like Tremfya that offer durable remission and reduced dosing frequency. Altogether, the confluence of growing patient populations supported by robust U.S. epidemiological data and Tremfya's effective, targeted profile is fueling market momentum and positioning it as a preferred therapy in managing chronic inflammatory diseases.

Key Market Challenges

High Treatment Costs

High treatment costs remain one of the most significant challenges impacting the Global Tremfya Market. Tremfya, being a biologic therapy, involves complex manufacturing processes, stringent quality controls, and advanced biotechnology infrastructure, all of which contribute to its high price point. The expense is further amplified by research and development costs, clinical trial investments, and regulatory compliance requirements. For many patients, particularly in low- and middle-income countries, the price of Tremfya places it beyond financial reach without robust insurance coverage or government subsidy programs. Even in developed markets, patients may face high out-of-pocket expenses, co-payments, or limitations in reimbursement policies, which can result in reduced adoption rates.

Healthcare systems often prioritize cost-effectiveness, and biologics like Tremfya must demonstrate clear value over existing therapies to justify coverage. This economic barrier can lead to delayed treatment initiation, therapy discontinuation, or a preference for cheaper alternatives, even if they are less effective. Pharmaceutical companies face the challenge of balancing innovation with affordability while navigating pricing negotiations with payers. The high treatment cost issue also influences competitive dynamics, as the emergence of biosimilars or alternative biologics with lower prices could erode market share. Addressing this challenge requires strategic pricing, value-based reimbursement models, and expansion of patient assistance programs to make Tremfya more accessible.

Key Market Trends

Increasing Adoption of IL-23 Inhibitors

The increasing adoption of IL-23 inhibitors is emerging as a defining trend in the Global Tremfya Market, driven by the growing recognition of their targeted therapeutic benefits in treating chronic immune-mediated inflammatory diseases. IL-23 inhibitors, such as Tremfya, block the p19 subunit of the interleukin-23 cytokine, a critical driver of inflammation in conditions like plaque psoriasis and psoriatic arthritis. This highly specific mechanism of action offers a favorable efficacy-to-safety ratio, making these drugs an attractive option for both physicians and patients, particularly those who have experienced suboptimal responses or adverse effects with older biologic classes such as TNF-alpha inhibitors or IL-17 blockers. The extended dosing intervals associated with IL-23 inhibitors, often every eight to twelve weeks after initial loading doses, enhance treatment adherence by reducing the frequency of injections, which is a significant advantage for patients managing lifelong conditions.

Clinical trial data and real-world evidence continue to validate the long-term durability of response and low immunogenicity risk, further building confidence in this drug class. Pharmaceutical companies are also expanding the scope of IL-23 inhibitor applications into new indications such as Crohn's disease and ulcerative colitis, which could substantially broaden their market potential. As prescriber familiarity grows and healthcare systems begin to recognize their long-term cost-effectiveness due to reduced disease flare-ups and improved quality of life, the uptake of IL-23 inhibitors is expected to accelerate. Strategic marketing efforts, patient support programs, and increased payer acceptance are contributing to their growing presence in treatment guidelines, reinforcing the trajectory of sustained adoption for Tremfya and its counterparts in the coming years. This trend reflects a broader shift in autoimmune disease management toward precision-targeted biologics that prioritize sustained remission, minimal side effects, and improved patient convenience.

Key Market Players

• Johnson & Johnson Services, Inc.
• Coherus BioSciences
• Amgen Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Pfizer Inc.
• AstraZeneca plc
• Sanofi S.A.
• Bristol-Myers Squibb

Report Scope:

In this report, the Global Tremfya Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tremfya Market, By Application:

• Plaque Psoriasis
• Psoriatic Arthritis (PsA)
• Others

Tremfya Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Tremfya Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tremfya Market.

Available Customizations:

Global Tremfya Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Tremfya Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Plaque Psoriasis, Psoriatic Arthritis (PsA), Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Tremfya Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tremfya Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Mexico Tremfya Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Canada Tremfya Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Distribution Channel

7. Europe Tremfya Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Tremfya Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Tremfya Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Tremfya Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Tremfya Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Tremfya Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Tremfya Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Tremfya Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Tremfya Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. South Korea Tremfya Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. Japan Tremfya Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Tremfya Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Distribution Channel

9. South America Tremfya Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Tremfya Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Tremfya Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Tremfya Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Tremfya Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Tremfya Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Tremfya Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Tremfya Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson & Johnson Services, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Coherus BioSciences
• 15.3. Amgen Inc.
• 15.4. AbbVie Inc.
• 15.5. Novartis AG
• 15.6. Eli Lilly and Company
• 15.7. Pfizer Inc.
• 15.8. AstraZeneca plc
• 15.9. Sanofi S.A.
• 15.10. Bristol-Myers Squibb

16. Strategic Recommendations

17. About Us & Disclaimer